J Karalliedde, RE Buckingham - Drug Safety, 2007 - ingentaconnect.com Thiazolidinediones (TZDs) or glitazones are agents that are widely used for the
Abstract treatment of type 2 diabetes mellitus. These drugs have a multitude of
therapeutic effects including reduction in insulin resistance and ... Cited by 15 - Related articles - BL Direct - All 6 versions
RB Goldberg - Current opinion in lipidology, 2007 - journals.lww.com Recent findings: During the past year, three new trials of thiazolidinediones
were reported. In Diabetes Reduction Assessment with Ramipril and Rosiglitazone
Medication, rosiglitazone reduced progression to diabetes in prediabetic ... Cited by 9 - Related articles - BL Direct - All 4 versions
RA Ajjan, PJ Grant - Expert Opin. Drug Saf., 2008 - informahealthcare.com Background: Thiazolidinediones (rosiglitazone, pioglitazone) influence insulin
sensitivity and are used for the treatment of Type 2 diabetes. Rosiglitazone
achieves sustained improvements in glycaemic control, whilst having ... Cited by 6 - Related articles - All 7 versions
- ►yoga-schule-augsburg.de [PDF] JS Volek, SD Phinney, CE Forsythe, EE … - Lipids, 2009 - Springer Abstract We recently proposed that the biological markers improved by
carbohydrate restriction were pre- cisely those that define the metabolic
syndrome (MetS), and that the common thread was regulation of insulin as a ... Cited by 6 - Related articles - All 12 versions
T Yang, S Soodvilai - PPAR research, 2008 - hindawi.com Thiazolidinediones (TZDs) are peroxisome proliferator-activated receptor subtype
γ (PPARγ) activators that are clinically used as an insulin sensitizer for
glycemic control in patients with type 2 diabetes. Additionally, TZDs ... Cited by 5 - Related articles - View as HTML - All 10 versions
CV Rizos, M Elisaf, DP Mikhailidis, EN … - Expert Opin. Drug Saf., 2009 - informahealthcare.com Background: Thiazolidinediones (TZDs) are widely used antidiabetic drugs with
proven efficacy regarding mainly surrogate markers of diabetes management.
However, efficacy on surrogate markers may not always translate into ... Cited by 5 - Related articles - All 5 versions
RB Goldberg, AJ Mendez - Journal of Clinical Lipidology, 2007 - Elsevier Decreased high-density lipoprotein cholesterol (HDL-C) levels have been
designated a major risk factor for cardiovascular disease, and there is
considerable interest in identifying individuals with these abnormalities ... Cited by 4 - Related articles - All 11 versions
